Introduction
============

The specific phosphorylation of inositol 1,4,5-trisphosphate (Ins(1,4,5)*P*~3~) in the 3-position (EC 2.7.1.127) was discovered 20 yr ago ([@bib2]; [@bib29; @bib30]). At that time it represented an unexpected complication in the metabolism of Ins(1,4,5)*P*~3~, whose second messenger function was just emerging ([@bib52]; [@bib3]). Moreover, given that we already knew that Ins(1,4,5)*P*~3~ can be inactivated by a specific 5-phosphatase (EC 3.1.3.56) ([@bib20]), it was something of a puzzle as to why cells should also consume ATP to phosphorylate Ins(1,4,5)*P*~3~. This conundrum was further enhanced when we found that Ins(1,3,4,5)*P*~4~ did not mobilize Ca^2+^ ([@bib29; @bib30]) so, superficially, Ins(1,4,5)*P*~3~ 3-kinase (IP~3~3 K) could indeed be viewed as just a 'redundant' off-switch for Ins(1,4,5)*P*~3~.

In the ensuing time, we have learned an enormous amount about the three members of the mammalian IP~3~3K family (for reviews of their overall molecular biology and properties see [@bib11]; [@bib28]; [@bib40]). We have also gone a long way towards an understanding of the 'why' question---why do cells bother to make Ins(1,3,4,5)*P*~4~, and consume an ATP molecule, when they have a perfectly good 5-phosphatase to inactivate Ins(1,4,5)*P*~3~? The answer to this question is a long and complicated one, and its principal components lie firstly in our knowledge of the evolution of the IP~3~3Ks and, secondly, in what we know about their localization and regulation.

Evolution of Ins(1,4,5)*P*~3~ 3-kinases
---------------------------------------

One of our major sources of enlightenment has stemmed from an understanding of where IP~3~3Ks came from. We now know that IP~3~3K is a member of a larger family of enzymes that began early in eukaryotic evolution ([@bib28]; [@bib27]), either as 'Ins*P*~3~ multi-kinases' (EC 2.7.1.151, i.e., inositol phosphate kinases that can phosphorylate several substrates), or Ins*P*~6~ kinases (EC 2.7.4.21). Together these enzymes form a major part of a route of synthesis of the pyro-phosphorylated inositol phosphates Ins(*PP*)*P*~5~ and Ins(*PP*)~2~*P*~4~ (more loosely known as Ins*P*~7~ and Ins*P*~8~, respectively). Discussion of these pathways and their functions can be found in, e.g., [@bib28]; [@bib48]; [@bib27]; [@bib55], and we return to them at the end of this review. Note that a particularly intriguing possible function for Ins(*PP*)*P*~5~ has emerged recently with the suggestion that it may directly (and non-enzymatically) phosphorylate some proteins, particularly proteins found in the nucleolus ([@bib44]).

From this recent cloning activity we can see that the IP~3~3Ks evolved out of an inositol phosphate kinase family late in eukaryotic evolution, probably about the time when metazoans emerged ([@bib28]). Moreover, from a comparison of the primary sequences of the family viewed in the context of how IP~3~3KA binds its Ins(1,4,5)*P*~3~ substrate with such exquisite specificity ([@bib24]), we can see that the crucial evolutionary change was the insertion of three extra *α*-helices in the Ins*P*-binding domain. This insertion holds the Ins(1,4,5)*P*~3~-binding residues in a precise orientation (see [Fig. 1](#fig1){ref-type="fig"}), and ensures an absolute specificity for the substrate, including not least ensuring that it will not phosphorylate PtdIns(4,5)*P*~2~ to generate the (already established when IP~3~3Ks evolved) second messenger PtdIns(3,4,5)*P*~3~ ([@bib24]; [@bib36]); note the contrast ([Fig. 1](#fig1){ref-type="fig"}) with the related 'Ins*P*~3~ multikinase', which lacks these three *α*-helices ([@bib24]), and can phosphorylate PtdIns(4,5)*P*~2~ to PtdIns(3,4,5)*P*~3~ ([@bib43]). So, as the first IP~3~3K emerged in the form of a specific Ins(1,4,5)*P*~3~ 3-kinase, why did evolution seize on it, keep it and use it extensively? The answer to this lies in the three possible functions of IP~3~3Ks, and it is these functions, and the regulation of the IP~3~3Ks' location and activity, that are the subject of the rest of this paper.

In simple terms, there are three possible functions for IP~3~3Ks: (a) to remove Ins(1,4,5)*P*~3~, thus terminating its second messenger function; (b) to synthesize Ins(1,3,4,5)*P*~4~, which acts as a second messenger in its own right; and (c) to serve as the first step in a route of synthesis of the higher inositol phosphates.

Functions (a)---removal of Ins(1,4,5)*P*~3~
-------------------------------------------

As hinted at above, to avoid redundancy of IP~3~3K with Ins(1,4,5)*P*~3~ 5-phosphatase as a remover of Ins(1,4,5)*P*~3~, we would expect there to be clear differences between the two enzymes in terms of their physiology. Indirect evidence for this comes from the different phenotypes engendered in *Caenorhabditis elegans* when the IP~3~3K ([@bib10]) versus the Ins(1,4,5)*P*~3~ 5-phosphatase ([@bib7]) are knocked out. The first difference in actual properties between the two enzymes to be discovered was that IP~3~3K has a higher affinity but lower *V*~max~ than Ins(1,4,5)*P*~3~ 5-phosphatase ([@bib29; @bib30]; [@bib15]), implying that perhaps IP~3~3K is the principal route of Ins(1,4,5)*P*~3~ metabolism in cells, with the phosphatase being there to remove rapidly any excess Ins(1,4,5)*P*~3~ (a relationship reminiscent of that between the high-affinity, low-capacity Ca^2+^-ATPases, and the low-affinity, high-capacity Ca^2+^/Na^+^ exchangers). One might, therefore, expect that at low doses of agonists (and thus at low Ins(1,4,5)*P*~3~ levels) the route of Ins(1,4,5)*P*~3~ metabolism is mostly by the kinase, and some data on inositol phosphates generated support that suggestion indirectly. But interestingly, in mice with either IP~3~3KA ([@bib31]) or IP~3~3KB ([@bib42]) knocked out, the authors reported no difference in Ins(1,4,5)*P*~3~ levels in relevant tissues, whereas in cells with reduced Ins(1,4,5)*P*~3~ 5-phosphatase, the authors documented increased Ins(1,4,5)*P*~3~ levels, leading to a change in cellular physiology ([@bib51]). These issues may be complicated by the possible existence of multiple pools of Ins(1,4,5)*P*~3~ (see ([@bib28] for discussion) and, overall, we still have no clear answer to the relative contributions of the two enzymes to Ins(1,4,5)*P*~3~ removal; it may be that it varies between tissues and organisms. More interesting and compelling evidence for a separation of the functions of the two enzymes lies in their very different regulation and localization.

At an early stage in its evolution, some time between the emergence of nematodes and arthropods ([@bib28]), IP~3~3K became regulated by Ca^2+^/calmodulin ([@bib11]). Later (in vertebrates), some IP~3~3K isoforms became activatable by phosphorylation on a threonine residue that is close to the catalytic site ([@bib24]) by CaMKII ([@bib12; @bib13]). This is in marked contrast to the inhibition of Ins(1,4,5)*P*~3~ 5-phosphatase caused by CaMKII phosphorylation ([@bib14]). Thus, an activation of CaMKII will divert Ins(1,4,5)*P*~3~ specifically towards Ins(1,3,4,5)*P*~4~, which might be taken as indirect evidence for some specific function of the latter (see below).

Another factor that separates the kinase and phosphatase is their distinctly different localization. The Ins(1,4,5)*P*~3~ 5-phosphatase is localized to the plasma membrane by being farnesylated ([@bib18]). However, the A and B isoforms of IP~3~3K are targeted either to the actin skeleton or to the endoplasmic reticulum (e.r.), and this targeting and its regulation represents a crucial aspect of their physiological function.

Localization of IP~3~3Ks
------------------------

The localization of the C isoform of IP~3~3K is controversial in that one group have claimed a partially nuclear (and dynamic) localization ([@bib37]), and the other a cytosolic localization ([@bib19]). We will not discuss this issue further, but will instead focus on the localization of the A and B isoforms, which is more fully understood.

IP~3~3KA is confined to the testis and to neurons, and in neurons its localization is dynamic and under tight regulation. IP~3~3KA is expressed at highest levels in the cerebellum and the hippocampus, especially in the neuropil of the CA1 and dentate gyrus regions of the latter ([@bib34]; [@bib45]). Moreover, this high level of enzyme is further concentrated by a clear localization to the post-dendritic spines of the neurons, a localization that is effected by a specific and novel F-actin binding domain consisting of the N-terminal 66 amino acids of IP~3~3KA ([@bib46]). In such a position, where it lies between the major site of Ins(1,4,5)*P*~3~ generation (by the post-synaptic density) and the site of its action (the e.r.), IP~3~3KA is perfectly poised to act as a sort of 'firewall' ([@bib46]), dictating by its activity the degree to which Ins(1,4,5)*P*~3~ can 'escape' from the spine and mobilize Ca^2+^ ([@bib46]). The acute and long-term regulation of IP~3~3KA by Ca^2+^ that is discussed above can then be viewed as a way in which stimulation of a spine to increase its Ca^2+^ will in turn dictate how it regulates the actions of Ins(1,4,5)*P*~3~.

We have explored this activation by Ca^2+^ in transfected cells (SML-B, JCHY, RFI and MJS, unpublished), and shown that even in a simple system like a HeLa cell, the influence of calmodulin and CaMKII is detectable in the ability of IP~3~3KA to decrease Ins(1,4,5)*P*~3~-induced Ca^2+^ mobilization. Moreover, the localization to the actin skeleton also has a clear effect on the efficacy of IP~3~3KA, again, even in such an unpolarized cell as a HeLa (SML-B, JCHY, RFI and MJS, unpublished), so when we consider such a highly polarized structure as a dendrite, the localization of IP~3~3KA adds a new dimension to the inter-relationship between the various stimulatory inputs into postsynaptic spines ([@bib46]).

Our more recent investigations of IP~3~3KA have now added another crucial dimension to this complexity, the dimension of time. Firstly, by using IP~3~3KA as a sort of real-time marker for F-actin, we have revealed that the F-actin in spines is in a highly dynamic state. As far as we can tell it is not turning over very rapidly, but rather the entire F-actin is in a state of dynamic equilibrium, whereby Ca^2+^ entry (especially through NMDA receptors) is driving it as a single entity out of the spines and into the main dendritic shaft ([Fig. 2](#fig2){ref-type="fig"} and ([@bib45])), carrying IP~3~3KA with it. This is a physiological response in so far as resting synaptic activity has a significant effect on IP~3~3KA localization ([@bib45]). Moreover, at high levels of stimulation with exogenous glutamate, which could be taken as a mimicking of massive stimulation such as follows ischemic shock, the exit of IP~3~3KA is total and rapid (within seconds), and may form the first stage in the pronounced changes in spine structure that follow such events ([@bib25]). It is important to note, however, that provided the stimulation with glutamate is not too prolonged, it remains fully reversible within about 20 min ([Fig. 2](#fig2){ref-type="fig"} and ([@bib45])). It remains to be seen what the functional consequences of this movement of IP~3~3KA are---as we have discussed elsewhere ([@bib45]); both removing IP~3~3KA from the spines and placing it in the shafts will have profound consequences for Ins(1,4,5)*P*~3~-mediated Ca^2+^ signalling. Moreover, as the principal Ins(1,4,5)*P*~3~-generating receptors in this system (metabotropic and muscarinic) have a minimal influence on IP~3~3KA movement, another consequence of these discoveries is to expand the complexity of the relationship between the different types of glutamate receptors.

Secondly, an extra layer of complexity in the dimension of time can be found in the spatial relationship between the e.r. and the actin skeleton. Our three-dimensional reconstruction of images ([@bib45]) has confirmed the close spatial relationship between these structures in those spines into which the e.r. penetrates ([@bib8]). However, all these images depict motionless structures, and the picture changes when we think about how spines themselves are moving ([@bib22]), and that movement itself impinges on the Ca^2+^ kinetics within the spine ([@bib35]). Moreover, we have shown that the e.r. itself is a highly motile organelle whose movements are under acute regulation by Ca^2+^ in both ATP-dependent and independent mechanisms ([@bib5; @bib6]). Taking this remarkable complexity concerning IP~3~3KA and the actions of Ins(1,4,5)*P*~3~ in dendrites overall, we can begin to see that there is no functional redundancy with Ins(1,4,5)*P*~3~ 5-phosphatase---in parallel experiments to those described above ([@bib45]), Ins(1,4,5)*P*~3~ 5-phosphatase does not localize to dendritic spines, but is instead distributed all along the plasma membrane of the dendrite, and it does not move perceptibly when glutamate is added (MJS and RFI, unpublished). Thus, it makes every sense that a primary function of IP~3~3KA could be to remove Ins(1,4,5)*P*~3~.

Finally, a brief consideration of IP~3~3KB supports this conclusion. Our understanding of the regulation of this isoform is not quite so advanced as for IP~3~3KA but, nevertheless, we know that in addition to its dual stimulation by CaM and CaMKII ([@bib13]), IP~3~3KB also has an interesting localization as a part of its function. Originally, it was described as being either cytosolic or in the e.r. ([@bib50]), but subsequent cloning of the full length enzyme (the original cloning was missing some of the N-terminus) has led to the realization that it is partially localized to the cytoskeleton ([@bib19]), because it too has an actin-binding domain ([@bib4]). The localization in the e.r. is due to a distinct part of the N-terminus ([@bib41]), and we have recently shown that removal of the first 150 amino acids from the N-terminus of IP~3~3KB causes the enzyme to move from the actin skeleton to the e.r. ([@bib56]). Moreover, this localization is subject to regulation by proteolytic cleavage ([@bib41]; [@bib56]), an event that we have shown takes place under physiological conditions, at least with the transfected enzyme ([@bib56]). Finally, as with the A-isoform (SML-B, JCHY, RFI and MJS, unpublished), the localization of the enzyme alters its ability to metabolize Ins(1,4,5)*P*~3~, as assayed by decreases in Ins(1,4,5)*P*~3~-induced Ca^2+^ signals ([@bib56]).

Functions (b)---synthesis of Ins (1,3,4,5)*P*~4~
------------------------------------------------

The possibility that Ins(1,3,4,5)*P*~4~ is a second messenger in its own right has been extensively discussed elsewhere (e.g. [@bib28]), and needs no expansion here. The only directly relevant recent information concerns our own attempts to gain evidence for the hypothesis ([@bib26]; [@bib49]; [@bib28]) that Ins(1,3,4,5)*P*~4~ acts to modify the structure of the e.r., thus regulating the mobilization of Ca^2+^ from the e.r. by Ins(1,4,5)*P*~3~. We have made concerted effort to seek evidence for such an effect on e.r. structure or movement using FRAP in several cell preparations, but have had to conclude either that the hypothesis is wrong, or that it cannot be detected by the technology we used ([@bib5; @bib6]). There remain intriguing and strong data showing that Ins(1,3,4,5)*P*~4~ can exert profound influences on Ins(1,4,5)*P*~3~-regulated Ca^2+^ homeostasis (e.g. ([@bib9]; [@bib33]), but the mechanism or universality of such responses remain unclear.

A very enticing indirect piece of evidence emerged recently from two independent reports that in the absence of the activity of IP~3~3KB, mice cannot mature their T cells, leading to immunocompromized animals ([@bib42]; [@bib54]). T lymphocyte Ca^2+^ signalling appeared superficially normal in both studies, and [@bib54] presented evidence that MAP kinase signalling might be altered. Both groups raised the issue that GAP1^IP4BP^, a putative Ins(1,3,4,5)*P*~4~ receptor ([@bib16; @bib17]), which is very highly expressed in circulating lymphocytes ([@bib32]), might be the protein involved, thus directly implicating Ins(1,3,4,5)*P*~4~ as the important factor missing in these mice.

Subject to some *caveats*, these findings are arguably the most compelling evidence yet that Ins(1,3,4,5)*P*~4~ is a physiological second messenger. The two *caveats* to this interpretation are, firstly that, as has been shown for many other proteins (including, e.g., the yeast Ins*P*~3~ multikinase ([@bib21]) and PI-PLC*γ* ([@bib39])), IP~3~3KB may play a structural role, independent of its catlytic activity, as an indispensible member of a multi-protein complex. The second *caveat* is that the important missing component may be Ins*P*~6~ (or another higher inositol phosphate), rather than Ins(1,3,4,5)*P*~4~.

Functions (c)---the first step in the synthesis of higher inositol phosphates
-----------------------------------------------------------------------------

The suggested synthesis pathway in mammalian cells for the higher inositol phosphates (functionally the most interesting of these are currently: Ins(3,4,5,6)*P*~4~, Ins(1,3,4,5,6)*P*~5~, Ins*P*~6~, Ins*P*~7~ and Ins*P*~8~ (see [@bib28]; [@bib48]; [@bib27] for reviews)) was first pieced together largely by Shears and Balla and their co-workers in the 1980s ([@bib1]; [@bib47]). The cloning of inositol phosphate kinases in the following decades culminated in the identification of all the enzymes responsible for this pathway ([Fig. 3](#fig3){ref-type="fig"}), which goes as: Ins(1,4,5)*P*~3~ to Ins(1,3,4,5)*P*~4~ to Ins(1,3,4)*P*~3~ to Ins(1,3,4,6)*P*~4~ to Ins(1,3,4,5,6)*P*~5~ to Ins*P*~6~ to Ins*P*~7~ (Ins*P*~7~ kinase has yet to be cloned).

If this is indeed the major pathway by which animals make Ins*P*~6~, then acting as the first step on it is another potentially very important function for IP~3~3Ks. Elsewhere, the arguments for and against whether other pathways of Ins*P*~6~ synthesis are equally or more important are discussed ([@bib27]), and these would not be repeated here. In this context, the crucial issue is whether the 'missing factor' in IP~3~3KB knock-out mice ([@bib42]; [@bib54]) is Ins(1,3,4,5)*P*~4~ itself, or another component of the above pathway. As mice lacking 'Ins*P*~3~ multikinase' ([@bib23]) or Ins*P*~5~ 2-kinase ([@bib53]) die at birth (compare the less severe phenotypes of IP~3~3K knock-out mice, above), superficially, it seems likely that IP~3~3K is not essential to higher inositol phosphate synthesis. We have recently set up a highly specific and sensitive mass assay for Ins*P*~6~ (RF I, AJL and MJS, unpublished), and by assessing the levels of Ins*P*~6~ in the above knock-out mice with this assay we hope to shed light on this issue.

Summary
=======

It is 20 yr since the Ins(1,4,5)*P*~3~ 3-kinase reaction was discovered, and this review summarizes and discusses some of the advances we have made in our understanding of the physiological significance of this reaction. The three major potential functions of Ins(1,4,5)*P*~3~ 3-kinases are discussed in the context of their localization and regulation, the possible functions of their product, Ins(1,3,4,5)*P*~4~ and their potential contribution to the synthesis of higher inositol polyphosphates.
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![Ins(1,4,5)*P*~3~ binding to IP~3~KA. This illustration is derived from the structure of IP~3~KA with Ins(1,4,5)*P*~3~ and ATP bound to it, as described by [@bib24]. On the left is the original structure, and on the right is exactly the same, but with the three-helices insert (IP lobe) that is unique to the Ins(1,4,5)*P*~3~ 3-kinases ([@bib24]) removed. Thus, the structure on the right envisions how Ins(1,4,5)*P*~3~ might bind to an Ins*P*~3~ multikinase (lacking these three helices) which could, therefore, enable a wider range of substrates binding, including PtdIns(4,5)*P*~2~ ([@bib43]).](gr1){#fig1}

![Dynamic localization of Ins(1,4,5)*P*~3~ 3-kinase A in postsynaptic spines. The figure shows IP~3~KA transfected into hippocampal neurones, and illustrates (A) before, (B) 2 min after, treatment with 100 μM glutamate, and (C) 20 min after removal of 100 μM glutamate and the addition of MK-801, an NMDA receptor antagonist. The reversible shift from the spines to the shaft induced by glutamate is plainly visible. See ([@bib45]) for all details.](gr2){#fig2}

![Pathways of Ins*P*~6~ synthesis. The figure depicts the two likely pathways for Ins*P*~6~ synthesis in mammlian cells. One route, the upper pathway ([@bib38]), is found in yeast, may exist in mammals and does not involve any Ins(1,4,5)*P*~3~ 3-kinase activity. The lower route ([@bib1]; [@bib47]) has IP~3~3K as an essential first step.](gr3){#fig3}
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